ImmuneRegen BioSciences, Inc. Announces Collaboration With the Department of Tumor Immunology of the Radboud University Nijmegen Medical Centre, the Netherlands

SCOTTSDALE, AZ--(Marketwire - April 27, 2010) - ImmuneRegen BioSciences Inc.®, a wholly owned subsidiary of IR Biosciences Holdings Inc. (OTCBB: IRBS), today announced a collaboration and research agreement with the Department of Tumor Immunology of the Radboud University Nijmegen Medical Centre (RUMC), in the Netherlands to commence studies utilizing ImmuneRegen's Homspera. Under the agreement top cancer vaccine experts at RUMC will perform exploratory studies on Homspera relating to its adjuvant and immunomodulatory properties for potential application in experimental cancer vaccines and immunotherapy for cancer.

Homspera has been shown to be effective in enhancing the efficacy of a novel cancer vaccine in an experimental melanoma model, and previous studies have demonstrated efficacy in enhancing immune responses to infectious disease vaccines, such as influenza. The studies to be performed at RUMC are designed to expand on that research, and further define the mechanisms that make Homspera an effective vaccine adjuvant.

The research will be directed by Professor Gosse Adema, Chair and full professor of Molecular Immunology in the Department of Tumor Immunology, Nijmegen Centre for Molecular Life Science. Professor Adema is also Theme Leader for Infection, Immunity and Tissue Repair. Dr. Adema has published over 150 scientific publications on scientific topics ranging from the role of dendritic cells in cancer immunology and cancer vaccines to the identification of cancer specific antigens. Other important RUMC Department of Tumor Immunology researchers who will participate in these studies with ImmuneRegen's Homspera include Dr. Jolanda de Vries and Professor Carl Figdor.

Radboud University Nijmegen Medical Centre is a leading academic centre with expertise in medical science and healthcare in the Netherlands. Scientific expertise plays an essential part in their organization and connects research, education and patient care. More than 8,000 staff and 2,500 students are committed and ambitious, helping to shape the future of healthcare and medical science.

"We are pleased that Professor Adema and his team are interested in evaluating the impact of Homspera in their cancer vaccine models, and hope this is the beginning of a long and fruitful relationship that takes our compound into a number of vaccine adjuvant, and perhaps other, studies," said Hal Siegel, Ph.D., ImmuneRegen's Chief Scientific Officer.

About ImmuneRegen BioSciences, Inc.
ImmuneRegen BioSciences Inc., a wholly owned subsidiary of IR BioSciences Holdings, Inc. (OTCBB: IRBS), is a development-stage biotechnology company focused on the research, development and licensing of Homspera®. Homspera is an adult stem cell active compound that in study results has been shown to regenerate and strengthen the immune system and enhance wound healing. Homspera is being developed for potential use against infectious diseases as a stand-alone or combination therapy. Additionally, Homspera is being developed for use as a therapeutic for Idiopathic Pulmonary Fibrosis, an indication which ImmuneRegen has recently submitted for Orphan Drug Status. To advance its mission, the Scottsdale, Arizona based company has forged numerous study partnerships with industry and academic leaders, including MPI Research, Celgene Cellular Therapeutics, HemoGenix, Lovelace Respiratory Research Institute and Virion Systems. For more information, please visit www.immuneregen.com.

Statements about ImmuneRegen's future expectations, including statements about the potential use and scientific results for ImmuneRegen's drug candidates, science and technology, and all other statements in this press release other than historical facts, are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Securities Litigation Reform Act of 1995. ImmuneRegen intends that such forward-looking statements be subject to the safe harbors created thereby. These future events may not occur as and when expected, if at all, and, together with ImmuneRegen's business, are subject to various risks and uncertainties. ImmuneRegen's actual results could differ materially from expected results as a result of a number of factors, including the uncertainties inherent in research and development collaborations, pre-clinical and clinical trials and product development programs (including, but not limited to the fact that future results or research and development efforts may prove less encouraging than current results or cause side effects not observed in current pre-clinical trials), the evaluation of potential opportunities, the level of corporate expenditures and monies available for further studies, capital market conditions, and others set forth in ImmuneRegen's periodic report on Form 10-Q for the three months ended September 30, 2009 as filed with the Securities and Exchange Commission and report on Form 10-K for the year ended December 31, 2009 as filed with the Securities and Exchange Commission. There are no guarantees that any of ImmuneRegen's proposed products will prove to be commercially successful. ImmuneRegen undertakes no duty to update forward-looking statements.